Literature DB >> 2965651

The major surface protein of Leishmania promastigotes is a fibronectin-like molecule.

F S Rizvi1, M A Ouaissi, B Marty, F Santoro, A Capron.   

Abstract

The major surface glycoprotein of Leishmania chagasi promastigotes showed crossreactivity with fibronectin (Fn), a large glycoprotein that is a major constituent of the extracellular matrix of most mononuclear cells. Polyclonal and monoclonal antibodies against Fn precipitated two molecules of 63-58 kDa from the lysates of both 125I and [35S]methionine-labeled promastigotes. In addition, a monoclonal antibody against a 15-kDa fragment of Fn containing the Arg-Gly-Asp-Ser (RGDS) sequence and several polyclonal monospecific mouse antibodies against a synthetic RGDS peptide also recognized the above two molecules. The attachment of Leishmania promastigotes to mouse peritoneal macrophages in vitro was partially inhibited when promastigotes were treated with F(ab')2 fragment of an anti-Fn IgG. Identical results were obtained by saturating the Fn receptors on macrophages using different peptides containing the RGDS sequence. Moreover, antigen preparations rich in glycoprotein 63 could efficiently promote the attachment and spreading of 3T3 mouse fibroblasts to surfaces coated with the antigen. These results clearly suggest that the gp63 of L. chagasi promastigotes is an Fn-like molecule that shares certain biological and molecular characteristics with Fn.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965651     DOI: 10.1002/eji.1830180323

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

Review 1.  Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival.

Authors:  Norikiyo Ueno; Mary E Wilson
Journal:  Trends Parasitol       Date:  2012-06-21

2.  Interaction of Leishmania gp63 with cellular receptors for fibronectin.

Authors:  A Brittingham; G Chen; B S McGwire; K P Chang; D M Mosser
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Antibodies raised against synthetic peptides from the Arg-Gly-Asp-containing region of the Leishmania surface protein gp63 cross-react with human C3 and interfere with gp63-mediated binding to macrophages.

Authors:  D G Russell; P Talamas-Rohana; J Zelechowski
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

Review 4.  Redundant and regulatory roles for Toll-like receptors in Leishmania infection.

Authors:  P Chauhan; D Shukla; D Chattopadhyay; B Saha
Journal:  Clin Exp Immunol       Date:  2017-08-07       Impact factor: 4.330

5.  Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody.

Authors:  María Colmenares; Stephanie L Constant; Peter E Kima; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family Trypanosomatidae.

Authors:  Antonio Campos-Neto; Isabelle Suffia; Karen A Cavassani; Shyian Jen; Kay Greeson; Pamela Ovendale; João S Silva; Steven G Reed; Yasir A W Skeiky
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

7.  Neoglycoproteins as tools for the detection of carbohydrate-specific receptors on the cell surface of Leishmania.

Authors:  J Schottelius
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

8.  Flagellum-mediated adhesion of Trypanosoma congolense to bovine aorta endothelial cells.

Authors:  A Hemphill; C A Ross
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

9.  Comparison of receptors required for entry of Leishmania major amastigotes into macrophages.

Authors:  R A Guy; M Belosevic
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

Review 10.  Innate immunity against Leishmania infections.

Authors:  Prajwal Gurung; Thirumala-Devi Kanneganti
Journal:  Cell Microbiol       Date:  2015-08-11       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.